STM publisher Springer, Germany, has signed an agreement with The Endocrine Society to co-publish a new journal, Hormones & Cancer, starting in January 2010. Jonathan Li of the Department of Pharmacology, Toxicology, and Therapeutics at Kansas University School of Medicine will serve as the Editor-in chief of the journal.
Hormonal cancers include two of the most deadly cancer subtypes - cancers of the breast and prostate. In addition to these cancers, Hormones & Cancer will include research articles covering other less-commonly occurring cancer subtypes, such as thyroid, gynecologic and pituitary cancer. The journal will help bridge the gap between those working in the two often disconnected fields of endocrinology and cancer research.
Hormones & Cancer is projected to be a translational journal, including basic scientific, epidemiological and clinical research papers. Because of the inherent multidisciplinary nature of the field, it is anticipated that the journal's focus will be on all aspects of hormone action on cancer causation, progression, dependence, prevention, resistance and treatment. Translational studies, especially those utilising novel cancer agents selectively designed to exert their action at hormone target tissues, will also be welcomed.
The journal will be published bimonthly both electronically and in print. The journal will include Cross Reference Linking, alert services, and online first, a feature by which articles are published online before they appear in print. The journal will be available on SpringerLink.com, a comprehensive collection of scientific, technological, and medical journals, books and reference works.
Search for more oncology products in K-Store
Discuss this NEWS
